Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATURN: Custirsen with Taxane for Pain in Second-Line mCRPC
NCT01083615Phase 3Terminated
- Sponsor
- Achieve Life Sciences
- Start
- Mar 2010
- Primary completion
- Mar 2013
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 5
01
Overview
A Phase 3 trial of custirsen in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Achieve Life Sciences. Started Mar 2010; status: terminated.
02
Drugs
custirsen
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01083615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01083615.